Targovax is invited to present at Neoantigen Summit Europe, DNB SME Conference and BIO-Europe Spring

Oslo, Norway, 19 March 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, announces that members of its senior management team is invited to present at upcoming conferences.

13th Annual BIO-Europe Spring, Vienna, Austria

Date: 25 March 2019
Presenter: Øystein Soug (CEO)

Panel discussion:
–    Art of multitrack deal: Keys to maximizing the value of your company
–    Time: 14:45 CET

DNB’s 15th Annual Small & Medium Enterprises (SME) Conference, Oslo, Norway

Date: 4 April 2019
Presenter: Øystein Soug (CEO)

Presentation:
–    Time: 13:45 CET

3rd Annual European Neoantigen Summit, Amsterdam, The Netherlands

Date: 25 April 2019
Presenter: Erik Digman Wiklund (CBO)

Presentation:
–    Title: TG Mutant RAS Neoantigen Vaccine: Signal of Clinical Benefit in Resected Pancreatic Cancer
–    Time: 12:00 CET

Presentations will be available to download at www.targovax.com after the event.

For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:

Andreas Tinglum – Corporate Communications
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient’s immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. Immuno-oncology is currently one of the fastest growing therapeutic fields in medicine.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect and replicate in cancer cells. It activates the immune system to generate tumor-specific immune responses. In a phase I monotherapy trial, ONCOS-102 induced both local and systemic innate and adaptive immune activation, with associated clinical benefit. In an ongoing phase I trial, patients who have progressed on anti-PD1 checkpoint inhibitors and treated with ONCOS-102 in combination with Keytruda, demonstrated responses in three of nine patients (33% ORR) including one complete response. ONCOS-102’s lead indication is mesothelioma, where the virus is currently being tested in a randomized phase I/II trial expected to report around new year 2019-20.